SGS is proud to be a partner and exhibitor at World Vaccine Congress EU 2020 – A Digital Event. Our experts will be pleased to share this virtual experience and welcome you to our virtual booth. Schedule a meeting with our experts.
About World Vaccine Congress EU 2020
The World Vaccine Congress is an award winning series of conferences and an exhibition that has grown to become the largest and most established vaccine meeting of its kind across the globe. Due to the global pandemic, this congress will be run virtually in 2020. Experts from around the globe will join together online to mobilize, coordinate and align funding to enable the research needed to tackle this crisis and stop the outbreak, and to share mechanisms for continued scientific interactions and collaborations.
Our Services
SGS serves pharmaceutical, biopharmaceutical, and medical device companies along the entire drug development pathway. With over 40 years’ experience as a global contract service organization, SGS provides integrated (bio)pharmaceutical development and testing solutions including clinical research, pharmaceutical development, biologics characterization, biosafety, and quality control testing for small and large molecules, raw materials, containers and finished products. SGS provides clinical research and bioanalytical testing, with a focus on early stage development and biometrics. Delivering solutions in Europe and North America, SGS offers clinical trial services. SGS has its own clinical unit in Belgium, including a viral challenge testing facility and two phase I patient units based in Belgium and Hungary. SGS has a wealth of expertise in FIH studies, viral challenge testing, biosimilars and complex PK/PD studies with a high therapeutic focus in infectious diseases, vaccines, and respiratory:
- Drug development consultancy
- Clinical pharmacology unit
- Clinical trial management in Europe and Americas
- Biometrics – data management, statistics, PK/PD and medical writing
- PK/PD modeling and simulation
- Regulatory and pharmacovigilance
SGS provides a comprehensive range of biosafety services such as: virology, cell and molecular biology as well as microbiology and electron microscopy. Health Authorities, including the US FDA and the EMA, require companies to undergo safety testing demonstrating that cell banks, viral banks, raw materials, bulk harvests, and batches of clinical drug are free of bacteria, fungi, mycoplasma, viruses and other potential contaminants. We help clients by ensuring product safety in satisfying these regulatory requirements. Our GLP/GMP facility is MHRA certified and US FDA audited. We provide:
- qPCR assays
- DNA sequencing (transgenes, viral vectors, plasmids)
- Identity Electron microscopy studies
- Adventitious agent detection
- Retrovirus detection
- Residual cell culture impurities
- Genetic Stability
- Microbial contaminants
- Biosafety consultancy services
For further information, please contact:
Clinical Research
t: +32 15 27 32 45